Top alert for 2014: MYGN (50%), LIVE (45%), CTIC (115%), KOOL (88%), PZG (32%), GOLD (6%), IOC (6%), RSOL(18%), PLUG (70%), IMMU (26%)

Thursday, February 6, 2014

Long Term Play Chart of the month: INFI


Infinity Pharmaceuticals, Inc. (IPI) is a drug discovery and development company. The Company's lead product is a potent, oral inhibitor of Class I PI3K-delta and PI3K-gamma, which the Company is investigating in both hematologic malignancies and inflammatory diseases.Its retaspimycin hydrochloride (HCl), is a potent and selective inhibitor of heat shock protein 90 (Hsp90). The phosphoinositide-3-kinases (PI3Ks) are key cellular signaling proteins that act as a central node for relaying signals from cell surface receptors to downstream biochemical events. The Company’s lead development candidate in this program is IPI-145 a potent, oral inhibitor of Class I PI3K-delta,gamma for which clinical trials are conducted form both hematologic malignancies and inflammatory diseases. Hematologic malignancies are cancers of the blood or bone marrow and include leukemia and lymphoma, such as chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, and non-Hodgkin lymphoma (NHL).
INFI chart buy when its moving, wait for earning to get over.


2014 Program Goals
Infinity anticipates achieving the following development milestones in 2014:
IPI-145 in Hematologic Malignancies
  • Initiate DYNAMO+R, a Phase 3 study in combination with rituximab in patients with relapsed/refractory iNHL
  • Initiate a Phase 2 study in treatment-na├»ve patients with iNHL
  • Initiate at least one additional clinical trial
IPI-145 in Inflammation
  • Report topline data from ASPIRA, a Phase 2 study of IPI-145 in patients with moderate-to-severe RA
  • Report topline data from the Phase 2a study of IPI-145 in patients with mild, allergic asthma
PI3K Pipeline Expansion
  • Announce development strategy for IPI-443
2014 Financial Guidance
Infinity entered 2014 with approximately $214 million in cash and investments (unaudited). Infinity plans to announce fourth quarter and full-year 2013 financial results in late February. The company is providing the following guidance today with respect to its 2014 financial outlook:
  • Operating Expenses: Infinity expects operating expenses for 2014 to range from $170 million to $180 million.
  • Net Loss: Infinity expects net loss for 2014 to range from $170 million to $180 million.
  • Cash and Investments: Infinity expects to end 2014 with a year-end cash and investments balance ranging from$40 million to $50 million. Based on its current operating plan and exclusive of any business development activities, Infinity’s financial foundation is expected to provide a cash runway into 2015.

No comments:

Post a Comment